Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein
- 14 May 2015
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 21 (10), 2359-2366
- https://doi.org/10.1158/1078-0432.ccr-14-1495
Abstract
Purpose: HHLA2 (B7H7/B7-H5/B7y) is a newly identified B7 family member that regulates human T-cell functions. However, its protein expression in human organs and significance in human diseases are unknown. The objective of this study was to analyze HHLA2 protein expression in normal human tissues and cancers, as well as its prognostic significance, to explore mechanisms regulating HHLA2 expression, and to identify candidate HHLA2 receptors. Experimental Design: An immunohistochemistry protocol and a flow cytometry assay with newly generated monoclonal antibodies were developed to examine HHLA2 protein. HHLA2 gene copy-number variation was analyzed from cancer genomic data. The combination of bioinformatics analysis and immunologic approaches was established to explore HHLA2 receptors. Results: HHLA2 protein was detected in trophoblastic cells of the placenta and the epithelium of gut, kidney, gallbladder, and breast, but not in most other organs. In contrast, HHLA2 protein was widely expressed in human cancers from the breast, lung, thyroid, melanoma, pancreas, ovary, liver, bladder, colon, prostate, kidney, and esophagus. In a cohort of 50 patients with stage I–III triple-negative breast cancer, 56% of patients had aberrant expression of HHLA2 on their tumors, and high HHLA2 expression was significantly associated with regional lymph node metastasis and stage. The Cancer Genome Atlas revealed that HHLA2 copy-number gains were present in 29% of basal breast cancers, providing a potential mechanism for increased HHLA2 protein expression in breast cancer. Finally, Transmembrane and Immunoglobulin Domain Containing 2 (TMIGD2) was identified as one of the receptors for HHLA2. Conclusions: Wide expression of HHLA2 in human malignancies, together with its association with poor prognostic factors and its T-cell coinhibitory capability, suggests that the HHLA2 pathway represents a novel immunosuppressive mechanism within the tumor microenvironment and an attractive target for human cancer therapy. Clin Cancer Res; 21(10); 2359–66. ©2014 AACR. See related commentary by Xiao and Freeman, p. 2201Other Versions
This publication has 31 references indexed in Scilit:
- Functional Clustering of Immunoglobulin Superfamily Proteins with Protein–Protein Interaction Information Calibrated Hidden Markov Model Sequence ProfilesJournal of Molecular Biology, 2013
- HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell functionProceedings of the National Academy of Sciences of the United States of America, 2013
- Functional Classification of Immune Regulatory ProteinsStructure, 2013
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- Intrinsic and extrinsic control of peripheral T‐cell tolerance by costimulatory molecules of the CD28/ B7 familyImmunological Reviews, 2011
- T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeuticsTrends in Molecular Medicine, 2011
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic CorrelatesJournal of Clinical Oncology, 2010
- Yin–Yang of costimulation: crucial controls of immune tolerance and functionImmunological Reviews, 2009
- The B7 Family and Cancer Therapy: Costimulation and CoinhibitionClinical Cancer Research, 2007
- B7x: A widely expressed B7 family member that inhibits T cell activationProceedings of the National Academy of Sciences of the United States of America, 2003